NEW YORK – Diaceutics and Alva10, two companies focused on facilitating evidence-based utilization of diagnostics in healthcare, are studying the economics of providing PD-L1 testing, and based on the data generated will develop a strategy to improve value-based reimbursement for labs providing such tests.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.